Prelude Therapeutics Inc revenue

Prelude Therapeutics Inc's revenue was $12.1m in fiscal 2025, up 73.4% on the year before. Over the last twelve months it was $22.4m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Prelude Therapeutics Inc: revenue history, annual
Fiscal year	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	7	12	22
Growth on the year before	—	+73.4%	—

US$ thousands unless shown otherwise. Fiscal quarters.

Prelude Therapeutics Inc: revenue history, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	3,000	4,000	0	0	6,500	5,640	4,580	5,704
Growth on the same quarter a year before	—	—	—	—	+116.7%	+41.0%	—	—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
Prelude Therapeutics Inc	$22.4m	220.3%	—
Janux Therapeutics, Inc.	$24.0m	5367.0%	45.7%
Crispr Therapeutics AG	$25.2m	-34.3%	-47.1%
Abeona Therapeutics Inc.	$25.5m	-87.7%	212.0%
Scynexis Inc	$19.2m	489.8%	-47.9%
Celularity Inc	$18.7m	-58.1%	7.2%

Compare with peers

Head to head: JANX vs PRLD CRSP vs PRLD ABEO vs PRLD

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Prelude Therapeutics Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Prelude Therapeutics Inc.